Mechanism and strategy of the secondary resistance to EGFR-TKI in patients with lung cancer

Abstract

Abstract:Epidermal growth factor receptortyrosine kinase inhibitor (EGFRTKI) is one of the most important targeted drugs for lung cancer patients carrying EGFR sensitive mutations. However, almost all patients that are effective to this treatment will eventually develop secondary resistance to EGFRTKI. The most accepted mechanisms of resistance mainly include T790M mutation, MET amplification, PIK3CA mutation, downregulation of PTEN expression and activation of Fastranscription factorκB. Recent years, many new drugs are developed to overcome this resistance. Although most of drugs are in the stages of cell or animal experiment, some new drugs get positive clinical results.

Key words:Lung neoplasms,Drug resistance, neoplasm,EGFR-TKI

CLC Number:

肺肿瘤|抗药性，肿瘤|表皮生长因子受体|酪氨酸激酶抑制剂

Liu Siwen, Yu Shaorong, Feng Jifeng. Mechanism and strategy of the secondary resistance to EGFR-TKI in patients with lung cancer[J]. Journal of International Oncology, 2015, 42(1): 56-59.

References

［1］ Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acidbased assay［J］. Clin Cancer Res, 2011, 17(5): 1169-1180. ［2］ Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant nonsmallcell lung cancer［J］. Nat Rev Cancer, 2010, 10(11): 760-774. ［3］ Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmallcell lung cancers dependent on the epidermal growth factor receptor pathway［J］. Clin Lung Cancer, 2009, 10(4): 281289. ［4］ Sequist LV, Waltman BA, DiasSantagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors［J］. Sci Transl Med, 2011, 3(75): 75ra26. ［5］ Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinibresistant lung cancer cells harboring epidermal growth factor receptoractivating mutations［J］. Cancer Res, 2010, 70(21): 8715-8725. ［6］ Suda K, Tomizawa K, Osada H, et al. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation［J］. Lung Cancer, 2012, 76(3): 292-299. ［7］ Uramoto H, Shimokawa H, Hanagiri T, et al. Expression of selected gene for acquired drug resistance to EGFRTKI in lung adenocarcinoma［J］. Lung Cancer, 2011, 73(3): 361365. ［8］ Bivona TG, Hieronymus H, Parker J, et al. FAS and NFκB signalling modulate dependence of lung cancers on mutant EGFR［J］. Nature, 2011, 471(7339): 523-526. ［9］ Sakuma Y, Yamazaki Y, Nakamura Y, et al. NFκB signaling is activated and confers resistance to apoptosis in threedimensionally cultured EGFRmutant lung adenocarcinoma cells［J］. Biochem Biophys Res Commun, 2012, 423(4): 667-671. ［10］ Nurwidya F, Takahashi F, Murakami A, et al. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer［J］. Cancer Res Treat, 2012, 44(3): 151-156. ［11］ Chung JH, Rho JK, Xu X, et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFRTKIs［J］. Lung Cancer, 2011, 73(2): 176-182. ［12］ Suda K, Tomizawa K, Fujii M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptormutant lung cancer cell line with acquired resistance to erlotinib［J］. J Thorac Oncol, 2011, 6(7): 1152-1161. ［13］ Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors［J］. Oncogene, 2013, 32(33): 3846-3856. ［14］ Tabara K, Kanda R, Sonoda K, et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells［J］. PLoS One, 2012, 7(7): e41017. ［15］ Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFRmutant lung cancers that lack the secondsite EGFRT790M mutation［J］. Cancer Discov, 2012, 2(10): 922-933. ［16］ Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic nonsmallcell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUXLung 1): a phase 2b/3 randomised trial［J］. Lancet Oncol, 2012, 13(5): 528-538. ［17］ Zhou W, Ercan D, Chen L, et al. Novel mutantselective EGFR kinase inhibitors against EGFR T790M［J］. Nature, 2009, 462(7276): 1070-1074. ［18］ Sun X, Zhang L, Tan H, et al. Multiscale agentbased brain cancer modeling and prediction of TKI treatment response: incorporating EGFR signaling pathway and angiogenesis［J］. BMC Bioinformatics, 2012, 13: 218. ［19］ van der Wekken AJ, Stigt JA, A′t Hart N. A novel EGFR mutation in exon 19 showed stable disease after TKI treatment［J］. J Thorac Oncol, 2012, 7(8): e8. ［20］ Wang W, Li Q, Takeuchi S, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factorinduced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer［J］. Clin Cancer Res, 2012, 18(6): 1663-1671. ［21］ Takeuchi S, Wang W, Li Q, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGFinduced EGFRTKI resistance in EGFR mutant lung cancer［J］. Am J Pathol, 2012, 181(3): 1034-1043. ［22］ Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase Ⅱ study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated nonsmallcell lung cancer［J］. J Clin Oncol, 2011, 29(24): 3307-3315. ［23］ Milhollen MA, Traore T, AdamsDuffy J, et al. MLN4 924, a NEDD8activating enzyme inhibitor, is active in diffuse large Bcell lymphoma models: rationale for treatment of NFκBdependent lymphoma［J］. Blood, 2010, 116(9): 1515-1523. ［24］ Witta SE, Jotte RM, Konduri K, et al. Randomized phase Ⅱ trial of erlotinib with and without entinostat in patients with advanced non-smallcell lung cancer who progressed on prior chemotherapy［J］. J Clin Oncol, 2012, 30(18): 2248-2255. ［25］ Li D, Shimamura T, Ji H, et al. Bronchial and peripheral murine lung carcinomas induced by T790ML858R mutant EGFR respond to HKI272 and rapamycin combination therapy［J］. Cancer Cell, 2007, 12(1): 81-93. ［26］ Sano T, Takeuchi S, Nakagawa T, et al. The novel phosphoinositide 3kinasemammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor［J］. Int J Cancer, 2013, 133(2): 505-513. ［27］ Huang MH, Lee JH, Chang YJ, et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib［J］. Mol Oncol, 2013, 7(1): 112-120. ［28］ Koizumi H, Yamada T, Takeuchi S, et al. Hsp90 inhibition overcomes HGFtriggering resistance to EGFRTKIs in EGFRmutant lung cancer by decreasing client protein expression and angiogenesis［J］. J Thorac Oncol, 2012, 7(7): 1078-1085.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng.Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection[J]. Journal of International Oncology, 2023, 50(12): 711-716.
[4]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin.Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging[J]. Journal of International Oncology, 2023, 50(11): 655-660.
[5]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun.Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model[J]. Journal of International Oncology, 2022, 49(9): 532-536.
[6]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying.Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses[J]. Journal of International Oncology, 2022, 49(8): 459-463.
[7]	Cai Gangxiang, Li Jing, Xu Bin.Advances in neoadjuvant immunotherapy for lung cancer[J]. Journal of International Oncology, 2022, 49(6): 366-370.
[8]	Zhang Jingxian, Yi Dan, Li Xiaojiang.Application of antibody-drug conjugates in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(5): 296-301.
[9]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei.Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer[J]. Journal of International Oncology, 2022, 49(4): 247-251.
[10]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 140-145.
[11]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming.Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(2): 111-115.
[12]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia.Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy[J]. Journal of International Oncology, 2022, 49(12): 718-723.
[13]	Zhang Hongjiao, Jiang Jie, Huang Wei.Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis[J]. Journal of International Oncology, 2022, 49(1): 51-55.
[14]	Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao.Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer[J]. Journal of International Oncology, 2021, 48(9): 523-526.
[15]	Wang Jun, Zhao Xia, Li Haifei, Zhang Cheng.Clinic diagnostic value of MSCT imaging features in nodular lung adenocarcinoma subtype[J]. Journal of International Oncology, 2021, 48(9): 537-543.